Answers are grounded in this paper and cite their sources.
Objective: This study aimed to identify the existing direct human evidence for blood neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as diagnostic and prognostic markers in hypertensive encephalopathy (HE), delineate the current boundaries of this evidence, and specify the necessary studies to expand it. Methods: A comprehensive search of PubMed/MEDLINE for human studies was conducted from inception to 24 September 2026. The search strategy combined a biomarker block (NfL, GFAP) with a HE block [hypertensive emergency, hypertensive crisis, malignant hypertension, posterior reversible encephalopathy syndrome, posterior reversible encephalopathy syndrome (PRES), pre-eclampsia, eclampsia], yielding 39 records. Screening excluded 25 records at the title and abstract stage and 4 at full text, resulting in 10 primary human studies. An additional 15 studies sourced providing pathophysiological background, contextual cerebrovascular evidence, and assay methodology were retrieved through targeted searches and reference-list hand-searching. These were selected purposively and not subjected to counted screening. In total, 25 sources are cited. Results: Ten human studies involving over than 1600 women provide direct evidence. In the largest phenotyped cohort, GFAP was 3.22 times higher (95% CI 2.06-5.02) in pre-eclampsia with neurological complications compared to uncomplicated pre-eclampsia, while NfL was not independently elevated; cerebral biomarkers outperformed angiogenic markers for the neurological phenotype. In obstetric PRES, serum NfL distinguished PRES from non-PRES cases (AUC 0.766 alone; 0.934 combined with headache) and correlated with the severity of vasogenic edema. NfL levels increase weeks before clinical pre-eclampsia, rise in cerebrospinal fluid in parallel with plasma, indicating a cerebral origin. Two findings limit interpretation: NfL levels rise significantly after uncomplicated delivery, and the markers are non-specific regarding the cause of injury. No study has measured NfL or GFAP in non-obstetric HE or hypertensive emergency. Conclusion: The evidence base for NfL and GFAP in HE is established but limited to obstetric phenotypes, where GFAP correlates with the neurological phenotype and NfL with axonal injury and edema severity. The limitation is not the absence of data but its confinement to pregnancy: non-obstetric hypertensive emergency remains entirely untested. Currently, neither marker can be recommended for clinical decision-making in HE. The priority is prospective cohorts in emergency department and intensive care populations with severe hypertension, employing standardized assays, serial sampling anchored to symptom onset, and age- and comorbidity-adjusted reference values.
No takes yet. Share an insight, caveat, or question.
Temirbaeva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: